Back to search results

EXPRESS+ Study: Methamphetamine Use and HIV

This study, called EXPRESS+, is looking at how a behavioral treatment called Contingency Management affects methamphetamine use and the body's stress response in men living with HIV. Contingency Management offers rewards, starting at $10 and increasing, for clean urine tests. We want to see if changes in your body's inflammatory (swelling) and Type I IFN (immune response) genes are connected to changes in your methamphetamine use and viral load over 12 weeks. You may be able to join if you are a man between 18 and 45 years old, living with HIV, and have used methamphetamine. The study is currently unclear about its recruitment status.

Study design
This is a non-randomized study with two groups, involving a total of 55 participants. One group receives Contingency Management, and the other is a control group.
What's involved
Participants will be observed over 8 weeks, with an additional follow-up 4 weeks later. Methamphetamine use will be measured twice weekly for 8 weeks in one group, and every 4 weeks for 12 weeks in the control group.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 4 weeks after the initial 8-week observation period, for a total of 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05558345

Expression of Stress Markers During Meth Treatment (EXPRESS+)

UNKNOWN
NAAges 18–45InterventionalTreatment
University of California, Los Angeles
~55 participants
Updated 2024-05-07 on ClinicalTrials.gov
What's tested:Contingency Management

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Inflammatory and Type I IFN Gene Expression over 12 weeks
Measured over every 4 weeks, at baseline, Week 4, Week 8, and Week 12
+1 more outcome measured

Conditions

Substance-Related Disorders
HIV

Explore related trials

HIV InfectionSubstance-Related Disorder

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Michael J Li, PhD · PRINCIPAL_INVESTIGATOR · UCLA Department of Family Medicine

Who to contact

Michael J Li, PhD
[email protected]
3107948530
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Change in Inflammatory and Type I IFN Gene Expression over 12 weeksevery 4 weeks, at baseline, Week 4, Week 8, and Week 12

    Change in gene expression values -- based on count per million or reference gene normalized mRNA extracted from leukocytes and mapped to 53 a priori specified genes -- averaged over 4 times points using mixed linear regression

  • Change in Methamphetamine Use over 12 weekstwice weekly for 8 weeks with 4-week follow-up in the contingency management group; once every 4 weeks over 12 weeks for the control group.

    Change in odds of methamphetamine use -- based on qualitative urine test result -- over 12 weeks.